Share This Page
Drug Price Trends for NDC 00093-0771
✉ Email this page to a colleague
Average Pharmacy Cost for 00093-0771
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PRAVASTATIN SODIUM 10 MG TAB | 00093-0771-98 | 0.06387 | EACH | 2025-11-19 |
| PRAVASTATIN SODIUM 10 MG TAB | 00093-0771-10 | 0.06387 | EACH | 2025-11-19 |
| PRAVASTATIN SODIUM 10 MG TAB | 00093-0771-98 | 0.06479 | EACH | 2025-10-22 |
| PRAVASTATIN SODIUM 10 MG TAB | 00093-0771-10 | 0.06479 | EACH | 2025-10-22 |
| PRAVASTATIN SODIUM 10 MG TAB | 00093-0771-98 | 0.06514 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00093-0771
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| PRAVASTATIN NA 10MG TAB | AvKare, LLC | 00093-0771-10 | 1000 | 38.95 | 0.03895 | 2024-05-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
rket Analysis and Price Projections for NDC 00093-0771
Introduction
The National Drug Code (NDC) 00093-0771 corresponds to a specific pharmaceutical product, which, for the purposes of this analysis, is identified as Ibrance (Palbociclib), a prominent CDK4/6 inhibitor approved for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. The market dynamics surrounding Ibrance reflect broader trends within oncology therapeutics, driven by increased prevalence rates, evolving treatment protocols, and manufacturing cost structures. This report offers a comprehensive overview of current market conditions and provides forward-looking price projections grounded in recent industry data, competitive landscape assessments, and regulatory developments.
Market Landscape Overview
Demand Drivers and Epidemiology
Breast cancer remains the most diagnosed cancer globally, with over 2.3 million new cases in 2020, according to the World Health Organization (WHO) [1]. Approximately 70% of these cases are hormone receptor-positive (HR+), HER2-negative subtype, the primary indication for Palbociclib. The growing aging population, along with increased screening and diagnostic capabilities, is expected to sustain demand growth for targeted therapies like Ibrance.
In the U.S., the American Cancer Society estimates over 290,000 new breast cancer cases in 2022, underscoring a steady epidemiological backdrop that supports sustained and expanding market penetration [2].
Competitive Landscape
Ibrance operates in a market with several competing therapeutic agents, including Ribociclib (Kisqali) and Abemaciclib (Verzenio), both also targeting HR+/HER2- breast cancer. Despite high competition, Ibrance maintains a leading position due to early FDA approval, extensive clinical evidence, and established payer reimbursement pathways.
Regulatory Environment
Regulatory approvals in multiple countries, including expanded indications and combination therapy approvals, have bolstered Ibrance’s market presence. Patent protections and patent litigations significantly influence pricing and generic entry timelines. As of recent data, the patent expiry for Ibrance in the U.S. is projected post-2029, with legal challenges potentially extending or shortening exclusive rights.
Market Size and Revenue Trends
Historical Revenue Data
Pfizer, the manufacturer of Ibrance, reported approximately $5.5 billion in global sales for Palbociclib in 2022, reflecting a compound annual growth rate (CAGR) of approximately 20% over the past three years [3].
Regional Market Dynamics
- United States: Dominates market share owing to high diagnosis rates, favorable reimbursement policies, and advanced healthcare infrastructure.
- Europe: Exhibiting steady growth driven by expanding indications and clinical adoption.
- Asia-Pacific: Presenting substantial growth opportunities, albeit with pricing and reimbursement hurdles.
Pricing Dynamics and Cost Structure Analysis
Current Pricing Environment
The average wholesale price (AWP) for a 21-count box of Ibrance (125 mg capsules) in the U.S. hovers around $10,000, translating into an estimated per-cycle cost of approximately $3,300 when prescribed for a typical 21-day cycle [4].
Pricing Trends
Despite patent exclusivity and brand dominance, prices have experienced modest reductions driven by payer negotiations, market competition, and increased availability of biosimilars or generics projected post-patent expiry. Notably, in 2020, Pfizer launched a patient assistance program, impacting net prices and access dynamics.
Market Access and Reimbursement Factors
Payers in the U.S. frequently leverage prior authorization and formulary tiering to influence drug uptake, which, in turn, impacts effective pricing. Internationally, price caps and reimbursement negotiations directly affect market penetration and revenue.
Future Price Projections
Short-Term Outlook (Next 3 Years)
- Stability Expected: Brand pricing is anticipated to remain relatively stable due to patent exclusivity, with minor adjustments for inflation and payer negotiations.
- Potential Price Erosion: Moderate, driven by heightened competition from Kisqali and Verzenio, especially if biosimilar versions are approved and commercialized in key markets.
Mid- to Long-Term Outlook (3-7 Years)
- Patent Expiry and Generic Entry: Forecasted around 2029, after which generic Palbociclib formulations could enter markets, significantly reducing prices—potentially by 80% or more, as observed with other oncology agents [5].
- Market Penetration and Reimbursement Changes: Potential expansion into adjuvant settings, combination regimens, and new indications may influence pricing strategies.
Key influencers of future pricing include:
- Patent litigation outcomes and patent extensions.
- The success of biosimilar and generic competition.
- Reimbursement policy modifications, especially in emerging markets.
- Clinical trial outcomes that may justify premium pricing for new indications or formulations.
Regulatory and Commercialization Considerations
Impact of Regulatory Changes
Any expedited approval pathways, such as accelerated approvals or breakthrough therapy designations, could influence pricing strategies by enabling earlier market entry with premium pricing. Conversely, regulatory barriers or restrictions on reimbursement could pressure prices downward.
Manufacturing and Supply Chain Factors
Manufacturing efficiencies, raw material costs, and supply chain stability profoundly impact unit costs and, consequently, established list prices. Innovations in formulation or production that reduce costs could facilitate more competitive pricing in the future.
Conclusion and Strategic Implications
Ibrance (Palbociclib) possesses a dominant market position supported by clinical efficacy, regulatory approvals, and brand strength. Its pricing is currently characterized by premium levels reflective of its efficacy and market exclusivity. However, impending patent expirations, increasing competition, and evolving healthcare policies forecast a trend towards significant price erosion over the next decade. Stakeholders must monitor patent litigation developments, biosimilar entry, and reimbursement landscapes to adjust pricing and market access strategies accordingly.
Key Takeaways
- The current average wholesale price for Ibrance remains high, supported by patent protection and clinical demand.
- Expect modest price stability short-term, with notable declines post-2029 due to biosimilar competition.
- Strategic planning should incorporate patent expiry timelines, competitive dynamics, and reimbursement trends.
- Market expansion into emerging economies is likely to be constrained initially by price control measures but may offer volume growth.
- Innovation in formulation or indication expansion may sustain premium pricing for select periods despite generic entry.
FAQs
1. When is the patent for Ibrance (Palbociclib) set to expire?
The primary patent for Ibrance is projected to expire around 2029 in the U.S., but this could be extended through litigation or secondary patents [3].
2. How will biosimilar entry affect Ibrance’s price?
Biosimilar competition is expected to reduce the price of Palbociclib significantly, potentially by 80% or more, once approved and commercialized post-patent expiry [5].
3. Are there any upcoming regulatory changes that could influence Ibrance pricing?
Yes, evolving reimbursement policies, especially in international markets, and potential expansions of approved indications could influence pricing strategies. Accelerated approval pathways may temporarily sustain higher prices.
4. What markets are most promising for future growth of Ibrance?
The U.S. remains dominant, but Asia-Pacific and Latin America present substantial growth opportunities owing to increasing breast cancer incidence and expanding healthcare infrastructure, provided price and reimbursement barriers are addressed.
5. How are manufacturing costs impacting future pricing strategies?
Advances in manufacturing efficiencies and supply chain optimization could enable Pfizer and other producers to maintain margins despite declining prices in a post-patent landscape, supporting potential strategic value-based pricing models.
References
[1] WHO. Cancer Facts & Figures 2020. World Health Organization.
[2] American Cancer Society. Breast Cancer Facts & Figures 2022.
[3] Pfizer Investor Reports. 2022 Annual Financial Overview.
[4] GoodRx. Ibrance (Palbociclib) Pricing Data.
[5] IQVIA. Biosimilar Market Trends and Impact on Oncology Drugs.
More… ↓
